ArticleJournal of the American Geriatrics Society2025
Effects of Initiating Different Antidepressant Subclasses on Motor Vehicle Crash Risk Among Older Adults With Depression.
Article in Journal of the American Geriatrics Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Long-Term Cardiovascular Risks of Anticholinergic Versus Non-Anticholinergic Antidepressants: A Target Trial Emulation With Negative Control Correction.Pharmacoepidemiology and drug safety · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAntidepressants are prescribed for depression among older adults but might increase the risk of motor vehicle crash (MVC) through adverse effects (AEs) like sedation, dizziness, and blurred vision. Antidepressant subclasses may have different MVC risks since AE risks vary across subclasses. Our objective was to estimate the comparative one-year risks of MVC upon initiating atypical (AA) or tricyclic (TCA) versus selective serotonin reuptake inhibitor (SSRI) antidepressants.
methodsWe emulated 470 sequential target trials each week from January 6, 2008, through January 1, 2017, using Medicare fee-for-service claims linked to New Jersey police-reported MVCs and driver's licensing data. Our sequential target trial emulation included older adults aged ≥ 66 years with a recent diagnosis of depression who initiated AAs, SSRIs, or TCAs. The unit of analysis was the "person-trial" a unique instance of a person in a sequential trial. Using inverse probability of treatment and censoring weighted Kaplan-Meier estimators to account for potential confounding and selection bias, we estimated the intention-to-treat cumulative incidence and risk ratios (RRs) of MVC over 1 year of follow-up.
resultsWe identified 13,034 person-trials from 11,604 persons (median [first quartile, third quartile] age: 76.0 [71.0, 82.0] years, 69.8% female, 89.4% non-Hispanic White race). There were 31 (37.6 [95% confidence limits {CLs} 20.3, 59.5] per 1000), 65 (37.6 [95% CLs 25.7, 47.7] per 1000), and 380 (38.0 [95% CLs 24.1, 39.7] per 1000) MVCs among 644 TCA-treated, 2130 AA-treated, and 10,260 SSRI-treated person-trials, respectively. The adjusted RRs were 0.99 (95% CLs 0.72, 1.56) comparing AAs versus SSRIs and 0.99 (95% CLs 0.56, 1.86) comparing TCAs versus SSRIs.
conclusionWe observed no differences in the one-year risk of MVC between antidepressant subclasses. When selecting among antidepressant subclasses to manage depression in older adults, MVC risk should not guide prescribing decisions, and other considerations should take precedence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.